ACYLATED GLUCAGON ANALOGUE

(19)

(11)

EP 3 283 507 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	13.11.2019 Bulletin 2019/46

(45)	Mention of the grant of the patent:
	02.10.2019 Bulletin 2019/40

(21)	Application number: 16717132.1

(22)	Date of filing: 15.04.2016

(51)

International Patent Classification (IPC):

A61K 38/22^(2006.01)
A61K 45/06^(2006.01)
A61K 31/155^(2006.01)
A61K 38/26^(2006.01)
A61K 31/7048^(2006.01)
A61K 31/365^(2006.01)

A61K 38/28^(2006.01)
A61K 31/137^(2006.01)
C07K 14/605^(2006.01)
A61K 31/135^(2006.01)
A61K 31/64^(2006.01)

(86)	International application number:
	PCT/EP2016/058359

(87)	International publication number:
	WO 2016/166289 (20.10.2016 Gazette 2016/42)

(54)	ACYLATED GLUCAGON ANALOGUE ACYLIERTES GLUCAGON-ANALOGON ANALOGUE ACYLÉ DU GLUCAGON

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

16.04.2015 EP 15163903

(43)	Date of publication of application:
	21.02.2018 Bulletin 2018/08

(73)	Proprietor: Zealand Pharma A/S
	2860 Søborg (DK)

(72)	Inventors:
	RIBER, Ditte DK-2600 Glostrup (DK) TOLBORG, Jakob Lind DK-2600 Glostrup (DK) HAMPRECHT, Dieter Wolfgang 55216 Ingelheim am Rhein (DE) THOMAS, Leo 55216 Ingelheim am Rhein (DE)

(74)	Representative: Mewburn Ellis LLP
	City Tower 40 Basinghall Street London EC2V 5DE London EC2V 5DE (GB)

(56)

References cited: :

US-A1- 2014 080 757

HJORTH S A ET AL: "GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1: SELECTIVE RECEPTOR RECOGNITION VIA DISTINCT PEPTIDE EPITOPES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 269, no. 48, 1 January 1994 (1994-01-01), pages 30121-30124, XP000919379, ISSN: 0021-9258
PAN CLARK Q ET AL: "Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 281, no. 18, 1 May 2006 (2006-05-01), pages 12506-12515, XP002529523, ISSN: 0021-9258, DOI: 10.1074/JBC.M600127200 [retrieved on 2006-02-27]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).